Ozempic
A GLP-1 receptor agonist developed by Novo Nordisk, with semaglutide as its active ingredient. It is indicated for the treatment of type 2 diabetes and obesity, and works by mimicking the intestinal hormone GLP-1 to regulate blood glucose levels and appetite.
Core Facts
Timeline (last 90 days)
GLP-1 receptor agonists were originally developed as diabetes treatments and work by regulating blood sugar and suppressing appetite.
GLP-1 drugs (represented by Ozempic) were originally used to treat type 2 diabetes and gained popularity due to their significant weight-loss effects.
Following reports of hair loss, an increasing number of users are reporting abnormalities such as brittle nails, slow nail growth, and ridging after using GLP-1 drugs.
Semaglutide is the active ingredient in Ozempic/Wegovy.
Ozempic (semaglutide) was originally a medication for treating type 2 diabetes.
Ozempic unexpectedly became one of the most disruptive weight-loss drugs in recent years, reshaping the obesity treatment industry.
The commercialization of Ozempic has been accompanied by controversies including high drug prices, global supply shortages, weight rebound after discontinuation, and insufficient long-term safety data.
The brain may be approaching an Ozempic-like turning point, with the emergence of scalable, highly accessible brain health pharmacological therapies.
All Facts (7)
GLP-1 drugs (represented by Ozempic) were originally used to treat type 2 diabetes and gained popularity due to their significant weight-loss effects.
65%UnverifiedGLP-1 receptor agonists were originally developed as diabetes treatments and work by regulating blood sugar and suppressing appetite.
50%UnverifiedSemaglutide is the active ingredient in Ozempic/Wegovy.
50%UnverifiedOzempic unexpectedly became one of the most disruptive weight-loss drugs in recent years, reshaping the obesity treatment industry.
50%UnverifiedThe commercialization of Ozempic has been accompanied by controversies including high drug prices, global supply shortages, weight rebound after discontinuation, and insufficient long-term safety data.
50%UnverifiedOzempic (semaglutide) was originally a medication for treating type 2 diabetes.
50%UnverifiedThe brain may be approaching an Ozempic-like turning point, with the emergence of scalable, highly accessible brain health pharmacological therapies.
50%